Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
SAB Biotherapeutics, Inc. (SABS) Receiveable Turnover data is not available for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$2.24M |
|
$-42.19M |
|
-- |
|
$2.24M |
|
$40.31M |
|
$-38.08M |
|
$-4.12M |
|
$-42.19M |
|
$-42.19M |
|
$-42.19M |
|
$-42.19M |
|
$-42.19M |
|
$-42.19M |
|
$-38.08M |
|
$-34.33M |
|
5.52M |
|
5.52M |
|
$-7.64 |
|
$-7.64 |
|
| Balance Sheet Financials | |
$58.91M |
|
$19.74M |
|
$25.03M |
|
$83.94M |
|
$10.81M |
|
$3.42M |
|
$15.83M |
|
$26.64M |
|
$57.30M |
|
$57.30M |
|
$57.30M |
|
9.28M |
|
| Cash Flow Statement Financials | |
$-25.12M |
|
$-0.15M |
|
$66.77M |
|
$15.05M |
|
$56.57M |
|
$41.52M |
|
$2.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.45 |
|
-- |
|
-- |
|
0.06 |
|
0.08 |
|
100.00% |
|
-1700.56% |
|
-1700.56% |
|
-1533.28% |
|
-1884.50% |
|
-1884.50% |
|
$-25.27M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
|
Receiveable Turnover |
-- |
-- |
|
-73.64% |
|
-73.64% |
|
-50.27% |
|
-69.49% |
|
$6.17 |
|
$-4.58 |
|
$-4.55 |
|